

## Introduction

Shanghai Henlius Biotech, Inc. is a joint venture company formed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Henlius Biopharmaceuticals Co., Ltd. in December 2009. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters and novel mAbs using cutting-edge technology. Registered in Shanghai Zhangjiang, we have so far invested over 400 million RMB in the early development of monoclonal antibody drugs.



Products currently in development cover a variety of therapeutic areas including oncology and autoimmune diseases. Our R&D management team has extensive experience in the development and commercialization of a range of monoclonal antibody drugs in such leading international pharmaceutical and biotech companies as Genentech, Amgen, BMS and Eli Lilly. The concept of our drug development lies in global integrative innovation, and we have 3 R&D laboratories located in China (Shanghai), the US (California) and Taiwan (Taipei).

Henlius is headquartered in the Shanghai Caohejing High-Technology Park. The total area of our Shanghai R&D laboratory is about 4,300m<sup>2</sup>, incorporating established development platforms of monoclonal antibody drugs. The company has completed the construction of a GMP standard facility with a 12,000 liter capacity, which adopted advanced disposable bioreactors based on the existing manufacturing facilities, ensuring the position of Henlius as a leading domestic antibody therapeutic testing and production site based in China.

In the eight years since its foundation, Henlius has been a leader in antibody drug development in China, completing the IND submissions of 12 product candidates with 20 indications. The most advanced product in our pipeline, the 'Recombinant Murine/Human Chimeric Anti-CD20 Monoclonal Antibody

Injection', and the second product HLX02 'Recombinant Humanized Anti-Her2 Monoclonal Antibody Injection' have both entered the Phase III study.